BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33847900)

  • 41. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sex as a Biologic Variable in Preclinical Imaging Research: Initial Observations with
    Chan SR; Salem K; Jeffery J; Powers GL; Yan Y; Shoghi KI; Mahajan AM; Fowler AM
    J Nucl Med; 2018 May; 59(5):833-838. PubMed ID: 29217733
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monitoring early responses to irradiation with dual-tracer micro-PET in dual-tumor bearing mice.
    Wang H; Liu B; Tian JH; Xu BX; Guan ZW; Qu BL; Liu CB; Wang RM; Chen YM; Zhang JM
    World J Gastroenterol; 2010 Nov; 16(43):5416-23. PubMed ID: 21086558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.
    Pio BS; Park CK; Pietras R; Hsueh WA; Satyamurthy N; Pegram MD; Czernin J; Phelps ME; Silverman DH
    Mol Imaging Biol; 2006; 8(1):36-42. PubMed ID: 16362149
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
    Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
    J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
    Yamane T; Takaoka A; Kita M; Imai Y; Senda M
    Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
    Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
    J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
    Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A
    PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival.
    Linecker A; Kermer C; Sulzbacher I; Angelberger P; Kletter K; Dudczak R; Ewers R; Becherer A
    Nuklearmedizin; 2008; 47(2):80-5; quiz N12. PubMed ID: 18392317
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
    Waldherr C; Mellinghoff IK; Tran C; Halpern BS; Rozengurt N; Safaei A; Weber WA; Stout D; Satyamurthy N; Barrio J; Phelps ME; Silverman DH; Sawyers CL; Czernin J
    J Nucl Med; 2005 Jan; 46(1):114-20. PubMed ID: 15632041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glucose-Thymidine Ratio as a Metabolism Index Using
    Oh S; Youn H; Paeng JC; Kim YH; Lee CH; Choi H; Kang KW; Chung JK; Cheon GJ
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012530
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
    Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats.
    Lee TS; Ahn SH; Moon BS; Chun KS; Kang JH; Cheon GJ; Choi CW; Lim SM
    Nucl Med Biol; 2009 Aug; 36(6):681-6. PubMed ID: 19647174
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of [18F]FDG uptake and distribution with hypoxia and proliferation in FaDu human squamous cell carcinoma (hSCC) xenografts after single dose irradiation.
    Bruechner K; Bergmann R; Santiago A; Mosch B; Yaromina A; Hessel F; Hofheinz F; van den Hoff J; Baumann M; Beuthien-Baumann B
    Int J Radiat Biol; 2009 Sep; 85(9):772-80. PubMed ID: 19657862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
    Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
    J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early detection of tumor response by FLT/microPET Imaging in a C26 murine colon carcinoma solid tumor animal model.
    Lee WC; Chang CH; Ho CL; Chen LC; Wu YH; Chen JT; Wang YL; Lee TW
    J Biomed Biotechnol; 2011; 2011():535902. PubMed ID: 21869861
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT.
    Kim HO; Kim JS; Shin YM; Ryu JS; Lee YS; Lee SG
    J Nucl Med; 2010 Dec; 51(12):1849-56. PubMed ID: 21098794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [
    Bak-Fredslund KP; Keiding S; Villadsen GE; Kramer S; Schlander S; Sørensen M
    Liver Int; 2020 Feb; 40(2):447-455. PubMed ID: 31705784
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study.
    Yue J; Chen L; Cabrera AR; Sun X; Zhao S; Zheng F; Han A; Zheng J; Teng X; Ma L; Ma Y; Han D; Zhao X; Mu D; Yu J; Li Y
    J Nucl Med; 2010 Apr; 51(4):528-34. PubMed ID: 20237030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.